After participating in these activities, learners will be better able to:

1. Evaluate the evolving landscape of HER2-targeted therapies and their role in optimizing treatment strategies for various cancer types.
2. Analyze the clinical efficacy and safety profiles of next-generation hormone therapies and PI3K inhibitors beyond CDK4/6 inhibitors in cancer treatment.
3. Assess the potential benefits and challenges of combining immunotherapies with antibody-drug conjugates (ADCs) to enhance therapeutic outcomes.
4. Understand evidence-based strategies for managing adverse effects of targeted therapies, improving patient adherence, and optimizing overall treatment efficacy.

1:00 - 2:00pm: Registration, Lunch, and Exhibits
2:00 - 2:05pm: Introduction
2:05 - 2:50pm: HER2-Targeted Therapies
2:50 - 3:35pm: Beyond CDK4/6 Inhibitors: Exploring Next-Generation Hormone Therapies and PI3K Inhibitors in Cancer Treatment
3:35 - 4:35pm: Break, Exhibits, Non-CME Ancillary Event, and Afternoon Pick-Me-Ups
4:35 - 5:20pm: Combining Target Mechanisms: Immunotherapies and Antibody-Drug Conjugates
5:20 - 6:05pm: Managing Adverse Effects of Targeted Therapies: Strategies for Optimizing Patient Outcomes
6:05 - 7pm: Networking Event

After participating in these activities, learners will be better able to:

1. Incorporate the latest advancements in the management of early-stage and late-stage lung cancer, including emerging therapeutic approaches.
2. Analyze new developments in pancreatic cancer treatment, with a focus on novel therapies and evolving clinical guidelines.
3. Assess the expanding role of antibody-drug conjugates (ADCs) in oncology and determine their appropriate integration into treatment strategies.
4.  Evaluate current approaches to CNS metastases management, assessing progress and identifying areas for continued improvement in patient care.

1:00 - 2:00pm: Registration, Lunch, and Exhibits
2:00 - 2:05pm: Introduction
2:05 - 2:50pm: Lung Cancer: Updates on Early-Stage and Late-Stage Disease
2:50 - 3:35pm: Pancreatic Cancer: A Refresher and the Latest Advances
3:35 - 4:35pm: Break, Exhibits, Non-CME Ancillary Event, and Afternoon Pick-Me-Up
4:35 - 5:20pm: Do We Really Need All These ADCs?
5:20 - 6:05pm: CNS Metastases: Are We Making Progress?
6:05-7:00pm: Networking Event

After participating in these activities, learners will be better able to:

1. Evaluate current and emerging CAR T-cell therapy strategies for lymphoid malignancies, including patient selection and response optimization.
2. Analyze the clinical efficacy and safety of triple-drug regimens in the treatment of relapsed/refractory acute myeloid leukemia (AML).
3. Assess the latest developments in BCMA-targeted treatment strategies for multiple myeloma and their impact on therapeutic decision-making.
4.  Integrate minimal residual disease (MRD) testing into multiple myeloma treatment decisions to optimize long-term patient outcomes.

1:00 - 2:00pm: Registration, Lunch, and Exhibits
2:00 - 2:05pm: Introduction
2:05 - 2:50pm: CAR T-Cell Therapy Strategies in Lymphoid Malignancies
2:50 - 3:35pm: Emerging Triple-Drug Regimens for Relapsed/Refractory AML
3:35 - 4:35pm: Break, Exhibits, Non-CME Ancillary Event, and Afternoon Pick-Me-Up
4:35 - 5:20pm: Advances in BCMA-Targeted Treatment Strategies for Multiple Myeloma
5:20 - 6:05pm: The Role of MRD Testing in Treatment Decisions and Outcomes for Multiple Myeloma
6:05-7:00pm: Networking Event

By CTA Train:
Green and Pink Lines: The nearest CTA station is Ashland, which serves both the Green and Pink Lines. From Ashland station, walk east along Lake Street to Ogden Avenue, then south to Fulton Street.

By Bus:
• Route 9 (Ashland): Disembark at the Lake Street stop, walk east to Ogden Avenue, then south
• Route 20 (Madison): Disembark at Ogden Avenue, then walk north to Fulton Street.

By Metra Train:
• Union Pacific West Line: Exit at Kedzie station. Transfer to the Route 20 (Madison) bus heading eastbound to Ogden Avenue, then walk north to Fulton Street.